Infectious Disease Diagnostics Market by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs) - Global Forecast to 2027
[294 Pages Report] The global infectious disease diagnostics market size is projected to reach USD 33.1 billion by 2027 from USD 35.5 billion in 2022, at a -1.4% CAGR. Market growth is driven by the global prevalence of infectious diseases and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID-19 Impact on Global Infectious Disease Diagnostics Market
COVID-19 is an infectious disease caused by the novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a few weeks. The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2020.
Since testing remains a crucial step in controlling the rapid spread of the disease, government organizations worldwide are supporting laboratories in streamlining COVID-19 testing procedures.The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the infectious disease diagnostics market because of the use of infectious disease diagnostic methods for COVID-19 testing.
In line with this, regulatory authorities utilized methods to speed up the approval of COVID-19 diagnostic products. Moreover, major companies have undertaken strategic developments to introduce COVID-19 rapid tests and nullify the impact of COVID-19 on their operational capabilities, as diagnostic testing remains the backbone of the COVID-19 response, supporting containment efforts to mitigate the outbreak. Also, the severity of this crisis and increasing capacity issues associated with PCR-based testing accelerated the development of diagnostic solutions to meet the demands for mass testing. Major companies operating in this market scaled up their operations for testing and tracking COVID-19.
However, the COVID-19 pandemic has continued to show a strong decline in the world this year, with contaminations decelerating everywhere, leading to a decrease in the growth rate of the infectious disease diagnostics market. Since the start of the COVID-19 outbreak, the WHO has worked with countries and areas in the Western Pacific Region on public health measures to slow or stop the spread of the virus. Vaccines are an important tool, in combination with other measures, to protect people against COVID-19 and reduce widescale social disruption.
Market Dynamics
Driver: Global prevalence of infectious diseases
The prevalence of infectious diseases in developed and developing regions will positively influence the growth of the infectious disease diagnostics market. The diagnosis and management of such diseases are responsible for the increasing number of prescriptions for infectious disease diagnostic tests. These factors, alongside the growing trend for preventive medicine, is expected to drive the demand for infectious disease diagnostics during the forecast period. The broad-scale population-based testing is required to improve prevention and control efforts for COVID-19. These tests are performed by infectious disease diagnostics; hence, it had a positive impact on this market.
Opportunity: Growing opportunities in growing economies
Developing economies such as India, South Korea, Brazil, and Mexico are expected to offer potential growth opportunities for major players operating in the infectious disease diagnostics market. This can be attributed to the high disease prevalence, large patient population, improving healthcare infrastructure, increasing disposable income, and growing medical tourism in these countries. In addition to the factors mentioned above, the Asia Pacific has emerged as an adaptive and business-friendly hub due to relatively less stringent regulations and data requirements.
Restraint: Unfavourable reimbursement scenario
Inadequate reimbursement is a major factor restraining the growth of the infectious disease diagnostics market. A major challenge that most diagnostic companies face in commercializing their tests is getting health insurers to pay for them.
In 2021, reagents, kits, and consumables segment accounted for the largest share of the infectious disease diagnostics market, by product & service”
The infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services, based on product & service. The reagents, kits, and consumables segment accounted for the largest share of this market in 2021. The recurrent usage of these products drives the market growth of this segment.
In 2021, immunodiagnostics segment accounted for the largest share in the market, by technology
The infectious disease diagnostics market is segmented into immunodiagnostics, PCR, clinical microbiology, INAAT, DNA sequencing & NGS, DNA microarray, and other technologies. In 2021, the immunodiagnostics segment accounted for the largest share. This can be attributed to the use of immunoassays in COVID-19 testing, POC infectious disease testing, the development of novel immunodiagnostic tests, and the rising trend of automation.
North America is the largest regional market for the infectious disease diagnostics
The global infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the global infectious disease diagnostics market in 2021. The North American infectious disease diagnostics market's growth can be attributed to the high burden of infections, growing healthcare expenditure, implementation of favorable government initiatives, improved healthcare infrastructures and the easy accessibility to technologically advanced instruments.
To know about the assumptions considered for the study, download the pdf brochure
Some key players in the infectious disease diagnostics market (2021- 2026)
- Abbott Laboratories (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Thermo Fisher Scientific Inc. (US)
- Siemens Healthineers AG (Germany)
- bioMérieux SA (France)
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
2020–2027 |
|
Base year considered |
2021 |
|
Forecast period |
2022–2027 |
|
Forecast units |
Value (USD Billion) |
|
Segments covered |
Product & Service, type of testing, technology, disease type, end user, and region |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
|
Companies covered |
Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Siemens Healthineers AG (Germany), Danaher Corporation (US), Becton, Dickinson and Company (US), PerkinElmer, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Grifols S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics Holdings plc (US), Quidel Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech Plc. (Ireland), Chembio Diagnostic Systems (US), Seegene, Inc. (South Korea), Co-Diagnostics (US), ELITechGroup (France), Epitope Diagnostics (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International (US), Vela Diagnostics (Singapore) and Uniogen Oy (Finland). |
This report categorizes the infectious disease diagnostics market into the following segments and subsegments:
By Product
- Reagents, Kits, and Consumables
- Instruments
- Software & Services
By Type of Testing
- Laboratory Testing
- POC Testing
By Technology
- Immunodiagnostics
- Clinical Microbiology
- PCR
- INAAT
- DNA Sequencing & NGS
- DNA Microarray
- Other technologies
By Disease Type
- COVID-19
- HIV
- Hospital-acquired Infections
- Hepatitis
- Chlamydia Trachomatis
- Neisseria Gonorrhea
- HPV
- Tuberculosis
- Influenza
- Syphilis
- Mosquito-borne Diseases
- Other Infectious Diseases
By End User
- Diagnostic Laboratories
- Hospitals & Clinics
- Academic Research Institutes
- Other End Users
By Region
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific (RoAPAC)
- Latin America
- Middle East & Africa
Recent Developments
- In November 2022, Roche Diagnostics Launched cobas 5800 system.
- In February 2021, Thermo Fisher Scientific acquired Mesa Biotech (US) to expand the benefits of molecular diagnostics at the point of care.
- In March 2020, Abbott Laboratories launched the ID NOW COVID-19 Test.
Frequently Asked Questions (FAQ):
What are the challenges affecting the infectious disease diagnostics market?
Challenges affecting the infectious diagnostics market is changing regulatory landscape.
What are the different types of testing in the infectious disease diagnostics market?
The infectious disease diagnostics market is segmented into laboratory testing and POC testing, based on type of testing. In 2021, the laboratory testing segment accounted for the largest share. This can be attributed to the increasing need for automation and the rising incidence of various diseases.
Who are the key players in the infectious disease diagnostics market?
The key players in this market are Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Siemens Healthineers AG (Germany), Danaher Corporation (US), Becton, Dickinson and Company (US), PerkinElmer, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Grifols S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics Holdings plc (US), Quidel Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech Plc. (Ireland), Chembio Diagnostic Systems (US), Seegene, Inc. (South Korea), Co-Diagnostics (US), ELITechGroup (France), Epitope Diagnostics (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International (US), Vela Diagnostics (Singapore) and Uniogen Oy (Finland).
Who are the key end-users of the infectious disease diagnostics market?
Based on end users, the infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic research institutes and other end users. In 2021, diagnostic laboratories accounted for the largest share of the infectious disease diagnostics market, mainly due to increasing test volume of infectious diseases and strengthening healthcare infrastructure for efficient disease diagnosis & treatment.
Which region is lucrative for the infectious disease diagnostics market?
The emerging economies in the Asia Pacific region will be the lucrative markets for infectious disease diagnostic products.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 32)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKETS SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION
FIGURE 2 MARKETS COVERED - BY REGION
1.3.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: YEARS CONSIDERED
FIGURE 3 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 37)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 4 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Primary sources
2.2.1.2 Key data from primary sources
2.2.2 PRIMARY DATA
2.2.2.1 Breakdown of primary interviews
2.2.2.2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
2.2.2.3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2.2.4 MARKET SIZE ESTIMATION
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Growth forecast
FIGURE 7 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
2.3.1.3 TOP-DOWN APPROACH
2.3.1.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 STUDY ASSUMPTIONS
2.7 LIMITATIONS
2.8 GROWTH RATE ASSUMPTIONS
2.9 RISK ASSESSMENT
2.9.1 RISK ASSESSMENT: INFECTIOUS DISEASE DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY (Page No. - 50)
FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 14 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 15 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 54)
4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW
FIGURE 16 RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD
4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 17 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO COMMAND LARGEST MARKET SHARE BY PRODUCT & SERVICE IN 2022
4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 18 IMMUNODIAGNOSTICS TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027
FIGURE 19 DIAGNOSTIC LABORATORIES TO DOMINATE END USER MARKET
5 MARKET OVERVIEW (Page No. - 57)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising technological advancements in infectious disease diagnostics
5.2.1.2 Shift in focus from centralized laboratories to decentralized POC testing
5.2.1.3 RESTRAINTS
5.2.1.4 Unfavorable reimbursement scenario
5.2.1.5 OPPORTUNITIES
5.2.2 RESTRAINTS
5.2.2.1 CHALLENGES
5.2.3 OPPORTUNITIES
5.2.3.1 Operational barriers
5.2.4 CHALLENGES
5.2.4.1 PRICING ANALYSIS
5.2.4.2 INDICATIVE PRICING MODEL ANALYSIS
5.2.5 IMPACT OF COVID-19 ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
5.3 PRICING ANALYSIS
5.3.1 INDICATIVE PRICING MODEL ANALYSIS
TABLE 1 INDICATIVE PRICE OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2022)
5.4 PATENT ANALYSIS
FIGURE 21 LIST OF MAJOR PATENTS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 23 INFECTIOUS DISEASE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM MARKET MAP
FIGURE 24 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ECOSYSTEM MARKET MAP
5.7.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT FROM NEW ENTRANTS
5.8.2 THREAT FROM SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 DEGREE OF COMPETITION
5.9 PESTLE ANALYSIS
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.2 NORTH AMERICA
5.10.2.1 EUROPE: CLASSIFICATION OF DEVICES
5.10.2.2 ASIA PACIFIC
5.10.3 EUROPE
TABLE 7 EUROPE: CLASSIFICATION OF DEVICES
5.10.4 ASIA PACIFIC
5.10.4.1 LATIN AMERICA
5.10.4.2 Brazil
5.10.4.3 Mexico
5.10.5 LATIN AMERICA
5.10.5.1 AFRICA
5.10.5.2 TRADE ANALYSIS
5.10.6 MIDDLE EAST
5.10.7 AFRICA
5.11 TRADE ANALYSIS
5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 8 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 9 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)
5.12 TECHNOLOGY ANALYSIS
5.13 KEY CONFERENCES & EVENTS IN 2022–2023
TABLE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14.1 REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19
5.14.2 REVENUE TO SHIFT IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
TABLE 11 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%)
5.15.2 BUYING CRITERIA
FIGURE 26 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
TABLE 12 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
5.16 CASE STUDY
FIGURE 27 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA
6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 84)
6.1 INTRODUCTION
TABLE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 14 PRICES OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2021)
6.2 REAGENTS, KITS, AND CONSUMABLES
6.2.1 RECURRENT PURCHASES OF REAGENTS, KITS, AND CONSUMABLES TO PROPEL MARKET GROWTH
TABLE 15 INFECTIOUS DISEASE DIAGNOSTIC REAGENTS, KITS, AND CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST INSTRUMENTS DEMAND
TABLE 16 KEY INSTRUMENTS AVAILABLE IN MARKET
TABLE 17 INFECTIOUS DISEASE DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.4 SOFTWARE & SERVICES
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE SEGMENT GROWTH
TABLE 18 INFECTIOUS DISEASE DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING (Page No. - 91)
7.1 INTRODUCTION
TABLE 19 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2020–2027 (USD MILLION)
7.2 LABORATORY TESTING
7.2.1 RISING INCIDENCE OF VARIOUS INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY REGION, 2020–2027 (USD MILLION)
7.3 POC TESTING
7.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE SEGMENT GROWTH
TABLE 21 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION, 2020–2027 (USD MILLION)
7.3.2 GLOBAL POC TESTING MARKET, BY END USER
TABLE 22 GLOBAL POC TESTING MARKET FOR INFECTIOUS DISEASES, BY END USER, 2020–2027 (USD MILLION)
TABLE 23 GLOBAL TESTS ADMINISTERED BY HEALTH PROFESSIONALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 24 GLOBAL CONSUMER SELF-TESTING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 25 US: POC TESTING MARKET FOR INFECTIOUS DISEASES, BY END USER, 2020–2027 (USD MILLION)
7.3.3 POC TESTING MARKET FOR INFECTIOUS DISEASES BY POINT OF PURCHASE AND POINT OF RESULT
TABLE 26 US: POC TESTING MARKET FOR INFECTIOUS DISEASES, BY POINT OF PURCHASE AND POINT OF RESULT, 2020-2027 (USD MILLION)
8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 97)
8.1 INTRODUCTION
8.2 PRIMARY NOTES
8.2.1 KEY INDUSTRY INSIGHTS
TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
8.3 IMMUNODIAGNOSTICS
8.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET GROWTH
TABLE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
8.3.2 IMMUNODIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY TYPE
TABLE 29 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION)
8.4 PCR
8.4.1 EMERGENCE OF ADVANCED TECHNOLOGIES SUCH AS QRT-PCR TO SUPPORT MARKET GROWTH
TABLE 30 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2020–2027 (USD MILLION)
8.5 CLINICAL MICROBIOLOGY
8.5.1 GROWING ADOPTION BY RESEARCHERS AND ACADEMIA TO DRIVE MARKET GROWTH
TABLE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2020–2027 (USD MILLION)
8.6 INAAT
8.6.1 COST BENEFITS OF INAAT TO DRIVE MARKET GROWTH
TABLE 32 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2020–2027 (USD MILLION)
8.7 DNA SEQUENCING & NGS
8.7.1 INCREASING USE OF NGS IN CANCER DIAGNOSIS TO FUEL MARKET GROWTH
TABLE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2020–2027 (USD MILLION)
8.8 DNA MICROARRAY
8.8.1 GROWING AWARENESS ABOUT ADVANCED TECHNOLOGIES TO DRIVE MARKET GROWTH
TABLE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAY, BY REGION, 2020–2027 (USD MILLION)
8.9 OTHER TECHNOLOGIES
TABLE 35 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE (Page No. - 106)
9.1 INTRODUCTION
TABLE 36 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
9.2 COVID-19
9.2.1 OUTBREAK OF COVID-19 PANDEMIC TO DOMINATE MARKET SHARE
TABLE 37 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2020–2027 (USD MILLION)
TABLE 38 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2020–2027 (MILLION TESTS)
TABLE 39 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY METHOD, 2020–2027 (USD MILLION)
9.3 HEPATITIS
9.3.1 INCREASING ADOPTION OF ADVANCED TECHNOLOGIES FOR HEPATITIS B DIAGNOSIS TO DRIVE SEGMENT GROWTH
TABLE 40 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2020–2027 (USD MILLION)
TABLE 41 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2020–2027 (MILLION TESTS)
TABLE 42 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY METHOD, 2020–2027 (USD MILLION)
9.4 HIV
9.4.1 HIGH GLOBAL PREVALENCE TO DRIVE SEGMENT GROWTH
TABLE 43 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2020–2027 (USD MILLION)
TABLE 44 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2020–2027 (MILLION TESTS)
9.5 HOSPITAL-ACQUIRED INFECTIONS
9.5.1 RISING BURDEN OF MRSA INFECTIONS TO DRIVE SEGMENT GROWTH
TABLE 45 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HAIS, BY REGION, 2020–2027 (USD MILLION)
TABLE 46 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HAIS, BY REGION, 2020–2027 (MILLION TESTS)
9.6 MOSQUITO-BORNE DISEASES
9.6.1 INCREASING INCIDENCE OF DENGUE TO DRIVE MARKET GROWTH
TABLE 47 MAJOR PRODUCTS: DENGUE TESTING
TABLE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2020–2027 (USD MILLION)
9.7 HPV
9.7.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2020–2027 (USD MILLION)
TABLE 50 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2020–2027 (MILLION TESTS)
9.8 CHLAMYDIA TRACHOMATIS
9.8.1 GROWING INCIDENCE OF CHLAMYDIA AND RISING AWARENESS AMONG PATIENTS TO DRIVE MARKET GROWTH
TABLE 51 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CT, BY REGION, 2020–2027 (USD MILLION)
TABLE 52 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CT, BY REGION, 2020–2027 (MILLION TESTS)
9.9 NEISSERIA GONORRHEA
9.9.1 RISING INCIDENCE OF GONORRHEA AND GROWING FUNDING FOR R&D TO DRIVE MARKET GROWTH
TABLE 53 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NG, BY REGION, 2020–2027 (USD MILLION)
9.10 TUBERCULOSIS
9.10.1 INCREASING BURDEN OF TUBERCULOSIS GLOBALLY TO DRIVE MARKET GROWTH
TABLE 54 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2020–2027 (USD MILLION)
TABLE 55 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2020–2027 (MILLION TESTS)
TABLE 56 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY METHOD, 2020–2027 (USD MILLION)
9.11 INFLUENZA
9.11.1 RISING FOCUS ON CONTROLLING INFLUENZA TO DRIVE MARKET GROWTH
TABLE 57 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2020–2027 (USD MILLION)
TABLE 58 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2020–2027 (MILLION TESTS)
TABLE 59 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY METHOD, 2020–2027 (USD MILLION)
9.12 SYPHILIS
9.12.1 GROWING ADOPTION OF NOVEL TECHNOLOGIES TO SUPPORT MARKET GROWTH
TABLE 60 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2020–2027 (USD MILLION)
9.13 OTHER INFECTIOUS DISEASES
TABLE 61 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER (Page No. - 124)
10.1 INTRODUCTION
TABLE 62 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2 DIAGNOSTIC LABORATORIES
10.2.1 INCREASING OUTSOURCING TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS TO LED TO LARGEST MARKET SHARE
TABLE 63 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
10.3 HOSPITALS & CLINICS
10.3.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS TO SUPPORT MARKET GROWTH
TABLE 64 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
10.4 ACADEMIC RESEARCH INSTITUTES
10.4.1 FOCUS ON DEVELOPING INNOVATIVE TESTS TO DRIVE MARKET GROWTH
TABLE 65 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
10.5 OTHER END USERS
TABLE 66 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION (Page No. - 130)
11.1 INTRODUCTION
TABLE 67 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
TABLE 68 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 69 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 70 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 71 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 72 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.1 US
11.2.1.1 Increasing prevalence of infectious diseases to drive market growth
TABLE 73 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 74 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 75 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 76 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Focus on affordable tests to drive market growth
TABLE 77 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 78 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 79 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 80 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 81 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 82 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 83 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 84 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 85 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Increasing healthcare expenditure to drive market growth
TABLE 86 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 87 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 88 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 89 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.2 UK
11.3.2.1 Growing number of accredited diagnostic laboratories to propel market growth
TABLE 90 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 91 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 92 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 93 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Rising R&D expenditure and increasing demand for early diagnosis to drive market growth
TABLE 94 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 95 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 96 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 97 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Adoption of advanced diagnostic technologies to drive market growth
TABLE 98 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 99 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 100 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 101 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Rising geriatric population to drive market growth
TABLE 102 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 103 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 104 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 105 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 106 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 107 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 108 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 109 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 29 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
TABLE 110 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 111 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 112 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 113 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 114 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Growing public access to modern healthcare to drive market growth
TABLE 115 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 116 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 117 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 118 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Universal healthcare reimbursement policy to drive market growth
TABLE 119 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 120 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 121 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 122 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Increasing private & public investments in healthcare system to drive market growth
TABLE 123 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 124 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 125 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 126 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 127 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 128 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 129 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 130 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 RISING DISEASE PREVALENCE AND HEALTHCARE EXPENDITURE TO DRAW FOREIGN PLAYERS
TABLE 131 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 132 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 133 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 134 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS TO SUPPORT MARKET GROWTH
TABLE 135 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 136 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 137 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 138 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 175)
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS
TABLE 139 OVERVIEW OF STRATEGIES DEPLOYED BY KEY INFECTIOUS DISEASE DIAGNOSTIC MANUFACTURING COMPANIES
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 30 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
12.4 MARKET SHARE ANALYSIS
12.4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET
FIGURE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2021)
TABLE 140 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION QUADRANT
12.5.1 LIST OF EVALUATED VENDORS
12.5.2 STARS
12.5.3 EMERGING LEADERS
12.5.4 PERVASIVE PLAYERS
12.5.5 PARTICIPANTS
FIGURE 32 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SMES (2021)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
12.7 COMPETITIVE BENCHMARKING
12.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
TABLE 141 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 142 COMPANY PRODUCT & SERVICE FOOTPRINT
TABLE 143 COMPANY REGIONAL FOOTPRINT
TABLE 144 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
12.8 COMPETITIVE SCENARIO
12.8.1 PRODUCT LAUNCHES
TABLE 145 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
12.8.2 DEALS
TABLE 146 KEY DEALS
13 COMPANY PROFILES (Page No. - 187)
(Business overview, Products offered, Recent Developments, MNM view)*
13.1 KEY PLAYERS
13.1.1 ABBOTT LABORATORIES
TABLE 147 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
TABLE 148 PRODUCT LAUNCHES & APPROVALS
13.1.2 F. HOFFMANN-LA ROCHE LTD.
TABLE 149 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
13.1.3 THERMO FISHER SCIENTIFIC INC.
TABLE 150 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 37 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
13.1.4 SIEMENS HEALTHINEERS AG
TABLE 151 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 38 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)
13.1.5 BIOMÉRIEUX SA
TABLE 152 BIOMÉRIEUX SA: BUSINESS OVERVIEW
FIGURE 39 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)
13.1.6 DANAHER CORPORATION
TABLE 153 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
13.1.7 HOLOGIC, INC.
TABLE 154 HOLOGIC, INC.: BUSINESS OVERVIEW
FIGURE 41 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
13.1.8 BECTON, DICKINSON AND COMPANY
TABLE 155 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
13.1.9 PERKINELMER, INC.
TABLE 156 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 43 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
13.1.10 SEEGENE, INC.
TABLE 157 SEEGENE, INC.: BUSINESS OVERVIEW
FIGURE 44 SEEGENE, INC.: COMPANY SNAPSHOT (2021)
13.1.11 QUIDEL CORPORATION
TABLE 158 QUIDEL CORPORATION: BUSINESS OVERVIEW
FIGURE 45 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
13.1.12 QIAGEN N.V.
TABLE 159 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 46 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
13.1.13 DIASORIN S.P.A
TABLE 160 DIASORIN S.P.A: BUSINESS OVERVIEW
FIGURE 47 DIASORIN S.P.A: COMPANY SNAPSHOT (2021)
13.1.14 BIO-RAD LABORATORIES, INC.
TABLE 161 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 48 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
13.1.15 GRIFOLS S.A.
TABLE 162 GRIFOLS S.A.: BUSINESS OVERVIEW
FIGURE 49 GRIFOLS S.A.: COMPANY SNAPSHOT (2021)
13.1.16 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC
TABLE 163 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW
FIGURE 50 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2021)
13.1.17 SYSMEX CORPORATION
TABLE 164 SYSMEX CORPORATION: BUSINESS OVERVIEW
FIGURE 51 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
13.2 OTHER PLAYERS
13.2.1 MERIDIAN BIOSCIENCE
13.2.2 ORASURE TECHNOLOGIES
13.2.3 CO-DIAGNOSTICS
13.2.4 CHEMBIO DIAGNOSTIC SYSTEMS
13.2.5 TRINITY BIOTECH PLC
13.2.6 GENETIC SIGNATURES LTD.
13.2.7 EPITOPE DIAGNOSTICS
13.2.8 TRIVITRON HEALTHCARE
13.2.9 ELITECHGROUP
13.2.10 MERIL LIFESCIENCES PVT. LTD.
13.2.11 INBIOS INTERNATIONAL
13.2.12 UNIOGEN OY
13.2.13 VELA DIAGNOSTICS
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX (Page No. - 287)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the infectious disease diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the infectious disease diagnostics market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the infectious disease diagnostics market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Global Infectious Disease Diagnostics Market Size: Top-Down Approach
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, segment, and forecast the global infectious disease diagnostics market by product & service, type of testing, technology, disease type, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
- To track and analyze company developments such as acquisitions, product launches and approvals, expansions, and other developments in the infectious disease diagnostics market.
- To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Country Information
- Infectious Disease Diagnostics market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa
Company profiles
- Company profiles of 30 players operating in the infectious disease diagnostics market
Growth opportunities and latent adjacency in Infectious Disease Diagnostics Market
What are the challenges faced by the key players of the Infectious Disease Diagnostics Market?
Which of the segments of Infectious Disease Diagnostics Market is expected to hold the major share?
How the technological innovations are boosting the global growth of Infectious Disease Diagnostics Market?